What action should a designated representative take upon discovering a drug shortage?

The appropriate action for a designated representative to take upon discovering a drug shortage involves reporting it to the proper authorities and managing inventory accordingly. This is crucial because drug shortages can impact patient care and public health, and therefore must be addressed systematically.

Reporting to the appropriate authorities, such as state health departments or the FDA, ensures that the shortage is documented and that necessary steps can be taken at a broader level to address it. This may include implementing strategies to alleviate the shortage or ensuring that patients are informed of alternative options.

In parallel, managing inventory responsibly is essential. A designated representative should assess current stock levels, prioritize the distribution of available medications, and communicate with healthcare providers about the situation. This proactive management helps prevent misuse of medications and ensures that limited resources are allocated in a manner that maintains patient safety.

The other options do not align with best practices or regulatory requirements. Engaging with the media prematurely or making public statements can lead to unnecessary panic without providing solutions. Purchasing from unauthorized suppliers introduces risks regarding the safety and efficacy of medications, and waiting for instructions from the manufacturer might delay critical action that could mitigate the impact of the shortage.